Brittany A. Davidson, MD, of Duke University, discusses the development and validation of the GO-POP model (Gynecologic Oncology Predictor of Postoperative opioid use), an individualized patient-centered predictive tool designed to help avoid overprescribing pain medications (ID# 10253).
Edward L. Trimble, MD, MPH, of the National Cancer Institute, discusses the World Health Organization’s global strategy to speed the elimination of cervical cancer through vaccination, screening, treatment, and training for multidisciplinary teams in gynecologic oncology care. This marks the first time that 194 countries have committed to such an effort (ID # 10203).
Sandro Pignata, MD, PhD, of the Istituto Nazionale dei Tumori, discusses results from the ORZORA trial, which showed the efficacy of olaparib in patients with platinum-sensitive relapsed ovarian cancer is similar, whether they have a germline or somatic BRCA mutation. This information could prove useful for clinical practice (ID #10226).
Eric Pujade-Lauraine, MD, PhD, of Hôpital Hôtel-Dieu, discusses results from the PAOLA-1ENGOT-ov25 trial on the use of homologous recombination–repair mutation gene panels and whether they can predict the efficacy of olaparib plus bevacizumab in first-line maintenance therapy for patients with ovarian cancer (ID# 10224).
Laura Chambers, DO, of the Cleveland Clinic, discusses data showing that combining paclitaxel and cisplatin vs cisplatin alone with hyperthermic intraperitoneal chemotherapy at interval debulking surgery improved progression-free survival. There was no difference in postoperative complications, length of stay, or time to chemotherapy, but admission to intensive care units did increase.
